NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
214 trialsNCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07077083 2026-03-11
CAIX PET/CT
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07072728 2026-03-03
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Phase 2 Recruiting
NCT07123090 2026-02-27
SPARCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT04258462 2026-02-23
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05487859 2026-02-17
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05239533 2026-01-14
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT06818305 2025-12-11
EmFin-Nx
Jinling Hospital, China
Phase 2 Terminated
NCT06962787 2025-11-17
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05842044 2025-09-05
No-PAIN
University of Miami
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT06948552 2025-04-29
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
Phase 2 Not yet recruiting
NCT04322955 2025-04-25
Cyto-KIK
Columbia University
Phase 2 Recruiting
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT03786796 2025-03-13
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04489771 2025-02-11
MK-6482-013
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06783348 2025-01-23
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT06760702 2025-01-07
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Recruiting
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02431676 2024-08-28
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05215470 2024-07-03
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das Clínicas de Ribeirão Preto
Phase 2 Active not recruiting
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06222125 2024-01-24
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Huabo Biopharm Co., Ltd.
Phase 2 Unknown
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT04021238 2023-11-13
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT00075660 2023-08-04
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00077129 2023-06-18
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02019693 2023-03-21
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT03387514 2022-12-21
UW17104
University of Wisconsin, Madison
Phase 2 Terminated
NCT05241561 2022-06-01
Cabo-POLARIS
Centre Hospitalier Universitaire de Besancon
Phase 2 Not yet recruiting
NCT00003656 2022-03-18
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn